Back

Upsher-Smith launches fluvoxamine extended-release capsules in 100 mg and 150 mg

Verifying
  • Upsher-Smith launched fluvoxamine extended-release capsules in two strengths.
  • IQVIA estimated U.S. market sales at approximately $44.6 million.
  • The product has an AB Therapeutic Equivalence code and Luvox CR as its reference drug.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.